TA211 Constipation (women) - prucalopride: review decision - January 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 126 KB)
-
TA211 Constipation (women) - prucalopride: review proposal - November 2013 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 449 KB)
-
Constipation (women) - prucalopride: press release information
-
Download PDF version
-
2010/179 NICE recommends prucalopride for chronic constipation in women (PDF 82 KB)
Constipation (women) - prucalopride: Equality Impact Assessment form
-
Constipation (women) - prucalopride: Equality Impact Assessment form
-
Constipation (women) - prucalopride: Equality Impact Assessment form (PDF 75 KB)
Constipation (women) - prucalopride: final appraisal determination
-
Constipation (women) - prucalopride: final appraisal determination information
-
Constipation (women) - prucalopride: final appraisal determination
-
Constipation (women) - prucalopride: final appraisal determination (PDF 249 KB)
-
Constipation (women) - prucalopride: response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Constipation (women) - prucalopride: consultee and commentator comments on the ACD
-
Constipation (women) - prucalopride: manufacturer
-
Constipation (women) - prucalopride: Movetis comments
-
Constipation (women) - prucalopride: Movetis comments (PDF 25 KB)
-
Constipation (women) - prucalopride: Movetis letter
-
Constipation (women) - prucalopride: Movetis letter (PDF 43 KB)
-
Constipation (women) - prucalopride: British Society of Gastroenterology and Royal College of Physicians (joint submission)
-
-
Constipation (women) - prucalopride: commentators
-
Constipation (women) - prucalopride: Norgine Pharmaceuticals Ltd comments on cost-effectiveness assessment
-
-
Constipation (women) - prucalopride: Norgine Pharmaceuticals Ltd comments on clinical assessment
-
-
Constipation (women) - prucalopride: West Midlands Health Technology Assessment Collaboration comments
-
-
Constipation (women) - prucalopride: comments on the ACD received from the public through the NICE website
-
Constipation (women) - prucalopride: web comments
-
Constipation (women) - prucalopride: web comments (PDF 291 KB)
-
Constipation (women) - prucalopride: public comments 1
-
Constipation (women) - prucalopride: public comments 1 (PDF 307 KB)
-
Constipation (women) - prucalopride: public comments 2
-
Constipation (women) - prucalopride: public comments 2 (PDF 7.3 KB)
Constipation (women) - prucalopride: press release on the draft guidance consultation
Constipation (women) - prucalopride: appraisal consultation
-
Constipation (women) - prucalopride: appraisal consultation
-
Constipation (women) - prucalopride: appraisal consultation document information
-
Constipation (women) - prucalopride: appraisal consultation: evaluation report
-
Constipation (women) - prucalopride: pre-meeting briefing
-
Constipation (women) - prucalopride: pre-meeting briefing (PDF 221 KB)
-
Constipation (women) - prucalopride: evidence review group report
-
Constipation (women) - prucalopride: evidence review group report (PDF 657 KB)
-
Constipation (women) - prucalopride: manufacturer response to the evidence review group report
-
Constipation (women) - prucalopride: Movetis letter to accompany response to ERG report
-
Constipation (women) - prucalopride: Movetis letter to accompany response to ERG report (PDF 81 KB)
-
Constipation (women) - prucalopride: Movetis critique of ERG report
-
Constipation (women) - prucalopride: Movetis critique of ERG report (PDF 174 KB)
-
Constipation (women) - prucalopride: non-manufacturer submissions
-
Constipation (women) - prucalopride: PromoCon statement
-
Constipation (women) - prucalopride: PromoCon statement (PDF 36 KB)
-
Constipation (women) - prucalopride: British Society of Gastroenterology statement
-
Constipation (women) - prucalopride: British Society of Gastroenterology statement (PDF 45 KB)
-
Constipation (women) - prucalopride: NHS Greenwich
-
Constipation (women) - prucalopride: NHS Greenwich (PDF 31 KB)
-
Constipation (women) - prucalopride: Movetis
-
-
Constipation (women) - prucalopride: NICE clarification letter
-
Constipation (women) - prucalopride: NICE clarification letter (PDF 66 KB)
-
Constipation (women) - prucalopride: Movetis response to NICE clarification letter
-
Constipation (women) - prucalopride: Movetis response to NICE clarification letter (PDF 458 KB)
-
Constipation (women) - prucalopride: expert statements
-
Constipation (women) - prucalopride: Whorwell
-
-
Constipation (women) - prucalopride: Emmanuel
-
-
Constipation (women) - prucalopride: Rogers
-
-
Constipation (women) - prucalopride: Amin
-
Constipation (women) - prucalopride: final scope
-
Constipation (women) - prucalopride: final scope
-
Constipation (women) - prucalopride: final scope (PDF 37 KB)
Constipation (women) - prucalopride: response to consultees and commentators on the draft scope
-
Constipation (women) - prucalopride: response to consultees and commentators on the draft scope
-
Constipation (women) - prucalopride: response to consultees and commentators on the provisional matrix
-
Constipation (women) - prucalopride: response to consultees and commentators on the provisional matrix
-